Merck Plans South San Francisco Research Facility
Merck has selected Alexandria Real Estate Equities to develop a biopharmaceutical R&D facility in South San Francisco, Calif. Construction will begin in early 2017 on the nine-story, 294,000-rsf building, the entirety of which will be leased by Merck. Designed by DGA to accommodate up to 300 scientists engaged in collaborative, multidisciplinary research, the facility will provide laboratories, offices, a 300-seat auditorium, a café, and a fitness center.